← All trials
NCT00002569
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 1994
- Primary completion
- Feb 1, 2005
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 299
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Radiation Therapy Oncology GroupLead sponsor
- Mayo ClinicStudy chair
- The University of Texas, DallasStudy chair
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- Southwest Oncology GroupCollaborator
- Eastern Cooperative Oncology GroupCollaborator
- Canadian Cancer Trials GroupCollaborator
- University of Western OntarioStudy chair
- Icahn School of Medicine at Mount SinaiStudy chair
- University of TorontoStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.